A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures

Charmi A Patel, Robert A Bailey, Ujjwala Vijapurkar, Gary Meininger, Lawrence Blonde, Charmi A Patel, Robert A Bailey, Ujjwala Vijapurkar, Gary Meininger, Lawrence Blonde

Abstract

Background: The randomized, double-blind CANTATA-SU (CANagliflozin Treatment And Trial Analysis Sulfonyl Urea) clinical trial compared the use of canagliflozin (100 mg or 300 mg) and maximally tolerated glimepiride (6-8 mg) over 104 weeks as add-on therapy for patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin. Compared with glimepiride, canagliflozin use was associated with durable reductions in glycated hemoglobin (A1C), blood pressure (BP), and body weight. The aim of this post-hoc analysis of the CANTATA-SU trial was to assess the comparative efficacy of canagliflozin and glimepiride in the attainment of recently updated diabetes-related quality measures (QMs) for up to 104 weeks of treatment.

Methods: This post-hoc analysis evaluated the proportions of patients achieving individual diabetes-related QMs using data from the randomized, double-blind, Phase 3 CANTATA-SU trial. Change in A1C from baseline, and proportions of the study population achieving QMs: A1C <7.0 %, <8.0 %, and >9.0 % were assessed. Secondary endpoints included change in BP from baseline, and the proportions of the study population achieving QMs related to BP and body weight.

Results: The proportions of patients in the canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride groups meeting criteria for all QMs were similar at baseline. At 52 and 104 weeks of treatment, canagliflozin 100 mg and canagliflozin 300 mg provided better or similar reductions in A1C from baseline and achievement of glycemic control QMs compared with glimepiride. At 52 and 104 weeks of treatment, the attainment of QMs related to reductions in body weight and BP all favored canagliflozin compared with glimepiride. Canagliflozin was associated with lower incidence of documented hypoglycemia and severe hypoglycemia compared with glimepiride.

Conclusions: Using the recently adjusted and currently accepted diabetes-related QMs, this analysis observed superior glycemic control with canagliflozin compared with maximally tolerated glimepiride in patients with T2DM who were previously poorly controlled on metformin monotherapy. Compared with maximally tolerated glimepiride, canagliflozin resulted in better achievement of diabetes-related QMs related to weight loss and BP, and was associated with lower incidences of hypoglycemic events.

Trial registration: Clinical trial registry name: CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride.

Clinical trial registration number: NCT00968812 , registered August 28, 2009.

Keywords: A1C; Blood pressure; Body weight; Canagliflozin; Glimepiride; Glycemic control; Phase 3; Post-hoc analysis; Quality measures.

Figures

Fig. 1
Fig. 1
Odds ratio (95 % CIs) of canagliflozin 100 mg vs. glimepiride and canagliflozin 300 mg vs. glimepiride in the proportion of patients achieving QMs at Week 52. Mean (SD) maximum dose of GLIM was 5.6 (2.3) mg. CANA, canagliflozin; GLIM, glimepiride; QMs, quality measures; SD, standard deviation; 95 % Cl, 95 % confidence interval
Fig. 2
Fig. 2
Odds ratio (95 % CIs) of canagliflozin 100 mg vs. glimepiride and canagliflozin 300 mg vs. glimepiride in the proportion of patients achieving QMs at Week 104. Mean (SD) maximum dose of GLIM was 5.8 (2.2) mg. CANA, canagliflozin; GLIM, glimepiride; QMs, quality measures; SD, standard deviation; 95 % Cl, 95 % confidence interval

References

    1. American Diabetes Association Standards of medical care in diabetes–2015. Diabetes Care. 2015;38(Suppl 1):S1–85.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2015;38:140–9. doi: 10.2337/dc14-2441.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–42. doi: 10.1007/s00125-014-3460-0.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364–79. doi: 10.2337/dc12-0413.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55:1577–96. doi: 10.1007/s00125-012-2534-0.
    1. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1–87. doi: 10.4158/EP15672.GLSUPPL.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438–47. doi: 10.4158/EP15693.CS.
    1. O’Connor PJ, Bodkin NL, Fradkin J, Glasgow RE, Greenfield S, Gregg E, et al. Diabetes performance measures: current status and future directions. Diabetes Care. 2011;34:1651–9. doi: 10.2337/dc11-0735.
    1. Dall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2014;37:3172–9. doi: 10.2337/dc14-1036.
    1. National Committee for Quality Assurance (NCQA) The state of health care quality. 2012.
    1. National Quality Measures Clearinghouse. Diabetes mellitus: percent of patients with a body mass index (BMI) greater than 25 who have lost 10 pounds at any time in the last 12 months. Agency for Healthcare Research and Quality website. . Accessed 4 December 2015.
    1. Cebul RD, Love TE, Jain AK, Hebert CJ. Electronic health records and quality of diabetes care. N Engl J Med. 2011;365:825–33. doi: 10.1056/NEJMsa1102519.
    1. Centers for Medicare & Medicade Services. Accountable Care Organization 2015 Program Analysis Quality Performance Standards Narrative Measure Specifications. . Accessed 8 September 2015.
    1. National Committee for Quality Assurance (NCQA) HEDIS 2015. 2015.
    1. National Committee for Quality Assurance (NCQA) Proposed Changes to Existing Measure for HEDIS ®1 2015: Comprehensive Diabetes Care (CDC) 2015.
    1. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58. doi: 10.1186/1472-6823-13-58.
    1. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–74. doi: 10.7326/0003-4819-159-4-201308200-00007.
    1. Wilding JP. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors. Metabolism. 2014;63:1228–37. doi: 10.1016/j.metabol.2014.06.018.
    1. Janssen Pharmaceuticals, Inc. Invokana (canagliflozin). Prescribing Information, revised 05/2016. . Accessed 8 Sept 2015.
    1. Bailey RA, Vijapurkar U, Meininger GE, Rupnow MF, Blonde L. Diabetes-related quality measure attainment: canagliflozin vs. sitagliptin based on a pooled analysis of 2 clinical trials. Am J Manag Care. 2014;20(Suppl 13):s296–305.
    1. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin vs. glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–50. doi: 10.1016/S0140-6736(13)60683-2.
    1. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks vs. glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–64. doi: 10.2337/dc13-2762.
    1. National Institutes of Health (NIH). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 98-4083. 1998. . Accessed 30 July 2015.
    1. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad Med. 2014;126:16–34. doi: 10.3810/pgm.2014.05.2753.
    1. Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF. Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events. Drug Saf. 2014;37(10):815–29. doi: 10.1007/s40264-014-0213-4.
    1. McGill JB. The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review. Diabetes Ther. 2014;5:43–63. doi: 10.1007/s13300-014-0063-1.
    1. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311:507–20. doi: 10.1001/jama.2013.284427.
    1. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121:94–107. doi: 10.3810/pgm.2009.09.2056.
    1. Grandy S, Fox KM, Hardy E, SHIELD Study Group Association of Weight Loss and Medication Adherence Among Adults With Type 2 Diabetes Mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes) Curr Ther Res Clin Exp. 2013;75:77–82. doi: 10.1016/j.curtheres.2013.06.004.
    1. Snel M, Sleddering MA, Vd Peijl ID, Romijn JA, Pijl H, Meinders AE, Jazet IM. Quality of life in type 2 diabetes mellitus after a very low calorie diet and exercise. Eur J Intern Med. 2012;23:143–9. doi: 10.1016/j.ejim.2011.07.004.
    1. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015
    1. Hine J, Paterson H, Abrol E, et al. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol. 2015;3:503–504. doi: 10.1016/S2213-8587(15)00204-1.
    1. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015;6:587–590. doi: 10.1111/jdi.12330.
    1. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686. doi: 10.2337/dc15-1251.
    1. Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015;38:1638–1642. doi: 10.2337/dc15-1380.
    1. Zinman B, Wanner C, Lachin JM, for the EMPA-REG OUTCOMES Investigators et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015
    1. Sjöström CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352–8. doi: 10.1177/1479164115585298.
    1. Wu HYJ, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–419. doi: 10.1016/S2213-8587(16)00052-8.
    1. Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014;63(12):1480–1490.40. doi: 10.1016/j.metabol.2014.09.002.
    1. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016;101(1):157–66. doi: 10.1210/jc.2015-3167.
    1. Medicare Shared Savings Program Quality Measure Benchmarks for the 2015 Reporting Year. 2015. . Acccessed 28 July 2015.
    1. Robert Wood Johnson Foundation. Health Affairs. Health Policy Brief . Pay-for-performance: new payment systems reward doctors and hospitals for improving the quality of care, but studies to date show mixed results. 2012.
    1. Integrated Healthcare Association Pay for Performance Measure Set Strategy: 2012–2015. 2015. . Accessed 26 October 2015.
    1. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP, Sitagliptin Study 024 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194–205. doi: 10.1111/j.1463-1326.2006.00704.x.
    1. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin vs. glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–22. doi: 10.2337/dc11-0606.
    1. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigator Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700. doi: 10.1016/S2213-8587(14)70120-2.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit